Molecular Imaging of Fibroblast Activation Protein in Response to Cardiac Injury Using [68Ga]Ga-DATA5m.SA.FAPi
<b>Background/Objectives:</b> Fibroblast activation protein (FAP) has gained tremendous traction as a target for tumor imaging and cancer treatment, while also playing a key role in fibrosis. Our study aimed to evaluate [<sup>68</sup>Ga]Ga-DATA<sup>5m</sup>.SA.FAPi for PET imaging of replacement fibrosis following myocardial infarction (MI) or interstitial fibrosis associated with hypertrophy. <b>Methods</b>: MI or transverse aortic constriction (TAC)-induced hypertrophy was induced in C57BL/6 mice, with sham-operated animals serving as controls. At multiple time points during disease progression (1, 2, and 6 weeks post-surgery), [<sup>68</sup>Ga]Ga-DATA<sup>5m</sup>.SA.FAPi PET/CT scans were performed, followed by ex vivo investigations. Additionally, in vitro cell uptake experiments simulating hypertrophy were conducted. <b>Results</b>: Cardiac uptake of [<sup>68</sup>Ga]Ga-DATA5m.SA.FAPi significantly increased two weeks after MI induction (MI: 2.1 ± 0.2%ID/g, <i>n</i> = 7 vs. SHAM: 1.1 ± 0.2%ID/g, <i>n</i> = 5; <i>p</i> = 0.002), confirmed by ex vivo autoradiography. No significant difference was observed at six weeks post-MI (MI: 1.1 ± 0.1%ID/g, <i>n</i> = 4 vs. SHAM: 0.8 ± 0.0%ID/g, <i>n</i> = 3), indicating infarct healing completion. In contrast, TAC mice showed increased uptake after six weeks (TAC: 1.8 ± 0.2%ID/g, <i>n</i> = 6; <i>p</i> = 0.007), related to interstitial fibrosis progression. Consistently, high-stretched cardiac fibroblasts demonstrated a higher uptake compared to low-stretched conditioned ones, suggesting the stretch mediates regulation of FAP. <b>Conclusions</b>: This study demonstrated the efficacy of [<sup>68</sup>Ga]Ga-DATA<sup>5m</sup>.SA.FAPi for longitudinal imaging of cardiac fibrosis in response to different cardiac injuries. In vivo FAP imaging during cardiac remodeling may serve as a valuable tool for diagnosing and predicting disease progression, ultimately aiding in the clinical management of patients.
Authors
- Lídia de Sousa (ORCID: https://orcid.org/0000-0002-8507-1443)
- Attila Kiss (ORCID: https://orcid.org/0000-0003-4652-1998)
- Michaela Schlederer
- Raffaella Calabretta (ORCID: https://orcid.org/0000-0002-8018-3884)
- Ana Isabel Antunes Goncalves (ORCID: https://orcid.org/0009-0009-3428-3321)
- Lukas Kenner (ORCID: https://orcid.org/0000-0003-2184-1338)
- Marcus Hacker (ORCID: https://orcid.org/0000-0002-4222-4083)
- Victoria Weissenböck
- Bruno Karl Podesser (ORCID: https://orcid.org/0000-0002-4641-7202)
- Thomas Nakuz (ORCID: https://orcid.org/0000-0002-9191-5235)
- Cécile Philippe (ORCID: https://orcid.org/0000-0002-7203-7174)
- Xiang Li (ORCID: https://orcid.org/0000-0002-0016-6233)
- Frank Rösch
- L. J. Weber
- Simge Baydar
- Anna Stampfer
Institutions
- University of Veterinary Medicine Vienna (AT)
- Johannes Gutenberg University Mainz (DE)
- Ludwig Boltzmann Institute for Cancer Research (AT)
- Ludwig Boltzmann Institute for Digital Health and Prevention (AT)
- Medical University of Vienna (AT)
Publication Details
- Journal
- Pharmaceuticals
- Published
- 2025-04-29
- DOI
- https://doi.org/10.3390/ph18050658
- Citations
- 1
- Primary Topic
- Peptidase Inhibition and Analysis
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Universität Wien
- Medizinische Universität Wien